Prognostic Value of Multiple Biomarkers in American Indians Free of Clinically Overt Cardiovascular Disease (from the Strong Heart Study)

American Journal of Cardiology

Volumn 104, Issue 2, 2009, Pages 247-253

  Kizer, Jorge R ^a   Krauser, Daniel G ^a   Rodeheffer, Richard J ^b   Burnett Jr , John C ^b   Okin, Peter M ^a   Roman, Mary J ^a   Umans, Jason G ^c   Best, Lyle G ^d   Lee, Elisa T ^e   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c MedStar Research Institute   (Colombia)

^d MISSOURI BREAKS INDUSTRIES RESEARCH INC   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AMERICAN INDIAN; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CREATININE URINE LEVEL; DEATH; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; RISK ASSESSMENT; RISK MANAGEMENT; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 67649378464     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.026     Document Type: Article

References (26)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Howard B.V., Best L.G., Galloway J.M., Howard W.J., Jones K., Lee E.T., Ratner R.E., Resnick H.E., and Devereux R.B. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29 (2006) 391-397
3. Folsom A.R., Chambless L.E., Duncan B.B., Gilbert A.C., and Pankow J.S. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 26 (2003) 2777-2784
4. Stevens R.J., Kothari V., Adler A.I., and Stratton I.M. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci Lond 101 (2001) 671-679
5. Yang X., So W.Y., Kong A.P., Ma R.C., Ko G.T., Ho C.S., Lam C.W., Cockram C.S., Chan J.C., and Tong P.C. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 101 (2008) 596-601
6. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
7. Danesh J., Lewington S., Thompson S.G., Lowe G.D., Collins R., Kostis J.B., Wilson A.C., Folsom A.R., Wu K., Benderly M., Goldbourt U., Willeit J., Kiechl S., Yarnell J.W., Sweetnam P.M., Elwood P.C., Cushman M., Psaty B.M., Tracy R.P., Tybjaerg-Hansen A., Haverkate F., de Maat M.P., Fowkes F.G., Lee A.J., Smith F.B., Salomaa V., Harald K., Rasi R., Vahtera E., Jousilahti P., Pekkanen J., D'Agostino R., Kannel W.B., Wilson P.W., Tofler G., Arocha-Piñango C.L., Rodriguez-Larralde A., Nagy E., Mijares M., Espinosa R., Rodriquez-Roa E., Ryder E., Diez-Ewald M.P., Campos G., Fernandez V., Torres E., Marchioli R., Valagussa F., Rosengren A., Wilhelmsen L., Lappas G., Eriksson H., Cremer P., Nagel D., Curb J.D., Rodriguez B., Yano K., Salonen J.T., Nyyssönen K., Tuomainen T.P., Hedblad B., Lind P., Loewel H., Koenig W., Meade T.W., Cooper J.A., De Stavola B., Knottenbelt C., Miller G.J., Cooper J.A., Bauer K.A., Rosenberg R.D., Sato S., Kitamura A., Naito Y., Palosuo T., Ducimetiere P., Amouyel P., Arveiler D., Evans A.E., Ferrieres J., Juhan-Vague I., Bingham A., Schulte H., Assmann G., Cantin B., Lamarche B., Després J.P., Dagenais G.R., Tunstall-Pedoe H., Woodward M., Ben-Shlomo Y., Davey Smith G., Palmieri V., Yeh J.L., Rudnicka A., Ridker P., Rodeghiero F., Tosetto A., Shepherd J., Ford I., Robertson M., Brunner E., Shipley M., Feskens E.J., Kromhout D., Dickinson A., Ireland B., Juzwishin K., Kaptoge S., Lewington S., Memon A., Sarwar N., Walker M., Wheeler J., White I., and Wood A. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1799-1809
8. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., and Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
9. 1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
10. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 (2007) 2357-2368
11. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., Wolf P.A., and Vasan R.S. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004) 655-663
12. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., Halle J.P., Young J., Rashkow A., Joyce C., Nawaz S., Yusuf S., and HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
13. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., and Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
14. Blankenberg S., McQueen M.J., Smieja M., Pogue J., Balion C., Lonn E., Rupprecht H.J., Bickel C., Tiret L., Cambien F., Gerstein H., Münzel T., Yusuf S., and HOPE Study Investigators. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 114 (2006) 201-208
15. Cook N.R., Buring J.E., and Ridker P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145 (2006) 21-29
16. Zethelius B., Berglund L., Sundstrom J., Ingelsson E., Basu S., Larsson A., Venge P., and Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008) 2107-2116
17. Lee E.T., Welty T.K., Fabsitz R., Cowan L.D., Le N.A., Oopik A.J., Cucchiara A.J., Savage P.J., and Howard B.V. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 132 (1990) 1141-1155
18. Best L.G., Zhang Y., Lee E.T., Yeh J.L., Cowan L., Palmieri V., Roman M., Devereux R.B., Fabsitz R.R., Tracy R.P., Robbins D., Davidson M., Ahmed A., and Howard B.V. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 112 (2005) 1289-1295
19. Zhang Y., Howard B.V., Cowan L.D., Welty T.K., Schaefer C.F., Wild R.A., Yeh J., and Lee E.T. Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic American Indian women: the Strong Heart Study. J Womens Health 13 (2004) 155-163
20. Palmieri V., Celentano A., Roman M.J., de Simone G., Best L., Lewis M.R., Robbins D.C., Fabsitz R.R., Howard B.V., and Devereux R.B. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J 145 (2003) 467-474
21. Lu W.Q., Resnick H.E., Jablonski K.A., Jain A.K., Jones K.L., Robbins D.C., and Howard B.V. Effects of glycaemic control on cardiovascular disease in diabetic American Indians: the Strong Heart Study. Diabet Med 21 (2004) 311-317
22. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., and Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008) 157-172
23. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., Jacques P.F., Rifai N., Selhub J., Robins S.J., Benjamin E.J., D'Agostino R.B., and Vasan R.S. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639
24. Standards of medical care in diabetes-2009. Diabetes Care 32 suppl (2009) S13-S61
25. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
26. Davidson M., Zhu J., Lu W., Tracy R.P., Robbins D.C., Resnick H.E., Ruotolo G., and Howard B.V. Plasminogen activator inhibitor-1 and the risk of type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med 23 (2006) 1158-1159